💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Neurocrine Biosciences, Inc. (NBIX)
« Back to company indexNBIX Chatter Timeline
Stock Ticker for NBIX
Most Active Tweeters for NBIX
| User | Tweets |
|---|---|
| @Estimize | 4 |
| @mediasentiment | 4 |
| @EdgarInsider | 2 |
| @Tickeron | 2 |
| @newsfilterio | 2 |
Recent Tweets for NBIX
 |
@badideasokay @popularinvestor @itsagelfert Thoughts on $NBIX earnings report? August 4th 2021, 11:08pm |
 |
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 937 August 4th 2021, 6:08pm |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 936 August 4th 2021, 6:08pm |
 |
@Jarvis_Alerts $NBIX [Neurocrine Biosciences]: Morgan Stanley Maintains Overweight Lowers Price Target $116 --> 110 charts: court… https://t.co/wp3VcKUCoT August 4th 2021, 2:08pm |
 |
@AlertTrade DYNAMO GAP UP $NBIX - Neurocrine Biosciences, Inc https://t.co/QtuL6kRIrr ? TradeIdeas via ? https://t.co/VS8RO1bzXJ August 4th 2021, 2:08pm |
 |
@quantisnow $NBIX ? Morgan Stanley reiterated coverage on Neurocrine Biosciences with a new price target https://t.co/xy4Wf2QcPu 30s delayed. August 4th 2021, 1:08pm |
 |
@newsfilterio Neurocrine Biosciences Reports Second Quarter 2021 Financial Results $NBIX https://t.co/EeEPVvTOyj August 4th 2021, 9:08am |
|
@newsfilterio Neurocrine Biosciences EPS misses by $0.13, beats on revenue $NBIX https://t.co/bwrmt91DrN August 4th 2021, 8:08am |
 |
@SeekingAlpha $NBIX - Neurocrine Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation. https://t.co/TBmOJ40WdT #markets #business #investing August 4th 2021, 8:08am |
 |
@maxm_profit RT @SeekingAlpha: $NBIX - Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2021 Results - Earnings Call Transcript. https://t.co/… August 4th 2021, 7:08am |
 |
@SiteFocusHQ $NBIX Earnings Intelligence Analysis of recent earnings identified Neurocrine Biosciences, Inc (NASDAQ: NBIX ) busi… https://t.co/YRviLrQLUZ August 4th 2021, 5:08am |
 |
@EarningsAlley Neurocrine Biosciences, Inc. $NBIX held an earnings call on 8/3/2021. Here are the highlights: August 4th 2021, 2:08am |
|
@SeekingAlpha $NBIX - Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2021 Results - Earnings Call Transcript.… https://t.co/0eSKlgcvbX August 4th 2021, 1:08am |
 |
@MarcJacksonLA $NBIX Neurocrine Biosciences Reports Second Quarter 2021 Financial Results https://t.co/7DBMYOmbsc August 4th 2021, 12:08am |
 |
@Briefingcom $NBIX: Neurocrine Biosci misses by $0.15, beats on revs https://t.co/VqiB2WjDl2 August 3rd 2021, 10:08pm |
 |
@Estimize The most accurate $NBIX estimate is from Cantor_20, beating 6 other analysts and the Wall Street Consensus - https://t.co/9I1cUlrI8a August 3rd 2021, 8:08pm |
|
@Estimize $NBIX misses the Estimize EPS Consensus by 19c and beats the Estimize Revenue Consensus by $10.89M. Reports FQ2 ear… https://t.co/90S4F4Uzlv August 3rd 2021, 8:08pm |
|
@Estimize $NBIX reports FQ2 earnings of 43c EPS and $288.90M Revs - https://t.co/PWhdnbhn58 August 3rd 2021, 8:08pm |
 |
@mehabecapital (Earnings) Neurocrine ( $NBIX ) Actual.EPS=0.63 vs Est.EPS=0.5076, Actual.Rev=288.9M vs Est.Rev=273.14M, Last Quote… https://t.co/Lg1aaYXPcN August 3rd 2021, 8:08pm |
 |
@realmaciej RT @BioStocks: $NBIX Q2 INGREZZA Net Product Sales $265M with ~ 48,900 Total Prescriptions. Phase 3 Registrational Program of Valbenazine… August 3rd 2021, 8:08pm |
 |
@EdgarInsider A Form 8-K [Press/News Current Report] filing has been made with the SEC: $NBIX NEUROCRINE BIOSCIENCES INC https://t.co/kWQhElOLMj August 3rd 2021, 8:08pm |
 |
@otcdynamics $NBIX Neurocrine Biosciences Reports Second Quarter 2021 Financial Results https://t.co/gjDesahECF August 3rd 2021, 8:08pm |
|
@EdgarInsider Filing Alert, FORM 10-Q [Quarterly Report] available. $NBIX NEUROCRINE BIOSCIENCES INC https://t.co/o04Jj6Yk30 August 3rd 2021, 8:08pm |
 |
@investor_feed $NBIX 10-Q Neurocrine Biosciences (3 Aug, 4:03pm) ? 2021 Q2 Earnings https://t.co/CIaTZoVBf4 #NBIX #10Q… https://t.co/GSLMr70ljh August 3rd 2021, 8:08pm |
 |
@FlashAlert_me $NBIX [15s. delayed] filed form 10-Q on August 03, 16:03:58 https://t.co/4VGfdwT5Mg August 3rd 2021, 8:08pm |
|
@investor_feed $NBIX 8-K Neurocrine Biosciences (3 Aug, 4:02pm) ? Neurocrine Biosciences Reports Second Quarter 2021 Financia… https://t.co/NsND1IPdbo August 3rd 2021, 8:08pm |
 |
@ethanFlare $NBIX - Neurocrine Biosciences EPS misses by $0.13, beats on revenue Cap size: mid, Float 98.7%, Short Interest 4.3… https://t.co/HsOsLa14Yo August 3rd 2021, 8:08pm |
 |
@BioStocks $NBIX Q2 INGREZZA Net Product Sales $265M with ~ 48,900 Total Prescriptions. Phase 3 Registrational Program of Val… https://t.co/kLc6rasjcG August 3rd 2021, 8:08pm |
 |
@MarketCurrents $NBIX - Neurocrine Biosciences EPS misses by $0.13, beats on revenue https://t.co/cMAAYRO1cV August 3rd 2021, 8:08pm |
 |
@StockNewsBot2 $NBIX Neurocrine Biosciences Reports Second Quarter 2021 Financial Results https://t.co/YuF1j8aAwa August 3rd 2021, 8:08pm |
 |
@stock_titan $NBIX Neurocrine Biosciences Reports Second Quarter 2021 Financial Results https://t.co/VBcohE0vii August 3rd 2021, 8:08pm |
|
@quantisnow $NBIX ? Neurocrine Biosciences Reports Second Quarter 2021 Financial Results https://t.co/8a02kVucjC 30s delayed. August 3rd 2021, 8:08pm |
 |
@StockPods $NBIX Earnings Call Today: 4:30 PM EST Webcast: https://t.co/Yu2QYYU2Mf Signup for the StockPods BETA now: https://t.co/Vma4E2hQ99 August 3rd 2021, 4:08pm |
|
@Estimize $NBIX reports after the close, Estimize Consensus +0.12 EPS and +4.82M Revs compared to WS - https://t.co/TcIAFjZ6Pn August 3rd 2021, 3:08pm |
 |
@Tickeron Neurocrine Biosciences, Inc. to report earnings on August 03, 2021. Earnings per share (EPS) estimate: $0.51 $NBIX… https://t.co/LWWDMVjnDs August 2nd 2021, 3:08pm |
|
@Tickeron $NBIX's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram just turned negative. View odds for th… https://t.co/AZCRSglhLk August 1st 2021, 11:08am |
 |
@TradeWithAlerts Large Print $NBIX Size: 102456 Price: 93.21 Time: 1600 Amount: $9,549,923.76 - Delayed - For real time prints subsc… https://t.co/ldetlTMBHT July 30th 2021, 8:07pm |
 |
@ShortAlgoTrades $NBIX Waiting for buy signal from UltraAlgo. https://t.co/sD98rXGoCZ July 30th 2021, 11:07am |
 |
@shortalgotrader $NBIX Waiting for buy signal https://t.co/cHOF4URXXj https://t.co/twrpv3vR5Q July 30th 2021, 11:07am |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 237 July 30th 2021, 10:07am |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 232 July 30th 2021, 10:07am |
 |
@InsiderForms $NBIX Insider Lloyd-Smith Malcolm has Sold 16,709 Shares. Title :Chief Regulatory Officer Total Cost: $1,567,335.95… https://t.co/1gVqDoyTVC July 29th 2021, 9:07pm |
 |
@day_trading_de NBIX (NEUROCRINE BIOSCIENCES INC) ? #Insider #stock alert! ? #Sale on 2021-07-27 - $NBIX ??: Lloyd-Smith Malcolm (C… https://t.co/l5c4IoJXYw July 29th 2021, 9:07pm |
 |
@stockmarkettile Neurocrine Biosciences $NBIX won FDA approval for its Parkinson’s drug Ogentys a few months ago. There could be si… https://t.co/JHHvUMaS8k July 25th 2021, 6:07am |
|
@newsfilterio Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results $NBIX https://t.co/YE1qiqYDkg July 20th 2021, 12:07am |
|
@FlashAlert_me $NBIX [15s. delayed]: Issued Press Release on July 19, 16:01:00: Neurocrine Biosciences Announces Conference Call a… https://t.co/7uT2DOWEMW July 19th 2021, 8:07pm |
|
@StockNewsBot2 $NBIX Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results https://t.co/z7IpievSv8 July 19th 2021, 8:07pm |
|
@stock_titan $NBIX Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results https://t.co/5kvvew3muN July 19th 2021, 8:07pm |
|
@quantisnow $NBIX ? Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results https://t.co/uPYQysfQXK July 19th 2021, 8:07pm |
|
@MarcJacksonLA $NBIX HC Wainwright Maintains Buy Rating On Neurocrine, $140 PT https://t.co/dbyqTCykAI July 17th 2021, 3:07pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?